INTRODUCTION
============

With a steady increase in the prevalence and associated comorbidities, diabetes has become one of the most significant socioeconomic burdens worldwide \[[@B1][@B2]\]. Due to the rising population at risk for diabetes \[[@B2][@B3]\], effective treatment and prevention measures have attracted much interest, recently. Although blood glucose and glycosylated hemoglobin levels are powerful predictors of diabetes development, there have been considerable efforts to improve the prediction model using several different biomarkers. However, few of these novel circulating and genetic biomarkers have proven valuable thus far \[[@B4][@B5]\]. From the pathophysiologic point of view, a compensatory increase in pancreatic β-cell mass or function in reOriginal sponse to insulin resistance precedes glucose intolerance \[[@B6]\]. In this context, biomarkers reflecting these processes may enhance the identification of individuals in the subclinical stages of diabetes progression.

Dynamic cross-talk between organs is fundamental in maintaining metabolic homeostasis and in the process of developing metabolic diseases \[[@B7]\]. Recently, a liver-derived β-cell growth factor has been suggested to induce β-cell proliferation against insulin resistant state in a liver-specific insulin receptor knockout mouse model \[[@B8]\]. Another study identified a liver and adipose tissue expressed hormone, betatrophin (also known as angiopoietin-like 8 \[ANGPTL8\], lipasin, TD26, and refeeding induced in fat and liver \[RIFL\]), which correlated with β-cell proliferation in the mouse model of pharmacologically induced severe insulin resistance \[[@B9]\]. Identification of the hormone betatrophin led to various human studies, which aimed to elucidate its association with metabolic states including diabetes. Many studies have shown differences in the circulating levels of betatrophin in the context of diabetes, insulin resistance, obesity, metabolic syndrome, or dyslipidemia; however, the results were inconclusive \[[@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28]\]. The relationship between circulating betatrophin concentrations and the risk of future diabetes is still unknown. Therefore, this study aimed to examine the predictive value of serum betatrophin levels in incident diabetes using a nested case-control design in a prospective cohort study.

METHODS
=======

Study subjects
--------------

The Institutional Review Board at The Catholic University of Korea approved this study (No. KCMC070T076, KC14SISI0885) and written informed consent was obtained from all participants. The Chungju Metabolic disease Cohort (CMC) study is a community-based longitudinal study of metabolic diseases, including diabetes, metabolic syndrome, and osteoporosis, in a population aged 40 years and over living in the rural area of Chungju, Korea \[[@B29][@B30]\]. A total of 334 districts were selected by stratified random cluster sampling, and participants were enrolled in the first phase of the study conducted in 2003 to 2006. Follow-up of the participants occured every 4 years (the second phase in 2007 to 2010 and the third phase in 2011 to 2014). There were 2,624 individuals who participated in both the second and third phases of the study. The present study was a nested case-control study, using the second phase as baseline and the third phase as follow-up. Among non-diabetic subjects at baseline, we identified 213 individuals (8.1%) who developed diabetes during the 4-year follow-up period. After excluding subjects lacking laboratory or anthropometric data and those without available serum samples, 167 individuals who developed diabetes were included in the analysis. For each of these individuals, we selected an individual from the non-converter group with a 1:1 matching propensity scores. Controls were matched for age, sex, and body mass index (BMI).

Study protocol
--------------

Investigators and survey personnel were trained in the study protocol prior to carrying out physical examinations and administering the questionnaire. Anthropometric measurements were performed with the participants wearing light clothing, and their height, weight, and waist circumference (WC) were measured to the nearest 0.1 cm and 0.1 kg per standardized methods. Blood pressure (BP) was measured twice on the right upper arm while the subjects were in a seated position after 5 minutes of rest, and the average was recorded. Hypertension was defined on the basis of the Joint National Committee 7 report as ≥140 (systolic BP)/90 (diastolic BP) mm Hg or when the subjects reported using antihypertensive medications. Detailed data on the lifestyle behavior and medical history of the participants were obtained by interview, and included inquieries concerning the subjects\' alcohol consumption (yes/no) and cigarette smoking (none, ex-smoker, or current smoker). Regular exercise was defined as three or more times per week for at least 30 minutes per session.

Biochemical assays and calculations
-----------------------------------

Blood samples were collected after the participants had fasted overnight for at least 12 hours and analyzed at a central laboratory (Neodin Medical Institute, Seoul, Korea). Fasting plasma glucose (FPG) was measured using the hexokinase method, and serum creatinine was measured using an enzymatic method. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease formula: 175×serum Cr (mg/dL)^−1.154^×Age (yr)^−0.203^×(0.742 if female). Serum total cholesterol (TC) and triglycerides (TG) were measured using enzymatic colorimetric tests. High density lipoprotein cholesterol was measured using a selective inhibition method, and low density lipoprotein cholesterol was calculated using the Friedewald formula. Serum high-sensitivity C-reactive protein levels were measured using a particle enhanced immunoturbidometric assay. Serum insulin levels were measured using a radioimmunoassay kit (Izotop, Budapest, Hungary), and the intra- and inter-assay coefficient of variance (CV) were \<5%. The homeostasis model assessment estimate of β-cell function (HOMA-β) and insulin resistance (HOMA-IR) were calculated using the following formulae: 20×fasting insulin (mIU/L)/\[FPG (mmol/L)--3.5\] and FPG (mmol/L)×fasting insulin (mIU/L)/22.5, respectively. Serum betatrophin levels were determined using a commercially available human enzyme-linked immunosorbent assay (ELISA) kit (Wuhan EIAab Science, Wuhan, China; Catalog No. E11644h) per the manufacturer\'s instructions. The intra- and inter-assay CV were 7% and 12%, respectively.

Definition of diabetes mellitus and metabolic syndrome
------------------------------------------------------

Diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) were defined according to the American Diabetes Association criteria. In the early period of the baseline study, an oral glucose tolerance test (OGTT) was performed if the FPG level exceeded 5.6 mmol/L. Beginning in September 2009, however, every participant underwent an OGTT, regardless of their FPG level. Every participant also underwent an OGTT for the diagnosis of glucose tolerance status during the follow-up period. Metabolic syndrome was defined using the American Heart Association/National Heart, Lung and Blood Institute criteria with modification of the WC value according to the World Health Organization--Asian Pacific region criteria for abdominal obesity as previously described \[[@B30]\].

Statistical analysis
--------------------

Data are expressed as the mean±standard deviation (SD), as medians (interquartile range) or as proportions. The characteristics of the subgroups were compared using Student *t*-tests, chi-squared tests or analysis of variance using the general linear model (GLM) procedure. Spearman\'s correlation analysis was used to examine the relationships between serum betatrophin concentrations and other parameters. A log-binomial regression model using the GENMOD procedure was performed to calculate the relative risk (RR) of serum betatrophin in predicting the development of diabetes. The variables with significant difference between non-converter and converter at baseline or known risk factors of diabetes were selected as covariates. RR and 95% confidence interval values of incident diabetes for the second through fourth quartiles were calculated using the lowest quartile as the reference category. All statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). A *P* value \<0.05 was considered significant.

RESULTS
=======

The mean age and BMI were 69.7±7.4 years and 22.9±2.9 kg/m^2^ for men and 67.3±8.5 years and 25.7±3.4 kg/m^2^ for women, respectively. [Table 1](#T1){ref-type="table"} shows a comparison of participant characteristics according to their glucose tolerance status at follow-up. At baseline, the subjects who had converted to diabetes had significantly higher levels of FPG and TC and a higher percentage of family history of diabetes compared to the non-converter group. Serum insulin levels, HOMA-IR, and HOMA-β were not significantly different between the two groups. At follow-up, the glucose levels obtained from OGTT, fasting insulin levels, and HOMA-IR were significantly higher in the converter group.

[Table 2](#T2){ref-type="table"} shows the mean betatrophin concentrations according to the baseline characteristic subgroups. Serum betatrophin concentrations were significantly higher in older, men, non-obese, non-abdominally obese, and hypertensive subjects compared to their counterparts. There were no significant differences between the subgroups according to metabolic syndrome, TG levels, eGFR, alcohol drinking, or the degree of insulin resistance. We calculated correlation coefficients between baseline serum betatrophin concentrations and glucose parameters in the baseline and during the follow-up period. At baseline, there were no significant correlations between betatrophin levels and FPG or insulin levels. Betatrophin levels were positively correlated with glucose levels at 120 minutes after OGTT (*r*=0.201, *P*\<0.001) and negatively correlated with insulin levels at 30 minutes after OGTT (*r*=−0.187, *P*=0.006) at follow-up. However, no significant relationships were observed between betatrophin levels and HOMA-IR, HOMA-β or insulin/glucose ratio. The correlation between betatrophin levels and lipid profiles was also insignificant.

Baseline serum betatrophin levels were significantly higher in the converter group than in the non-converter group (1,315±598 pg/mL vs. 1,072±446 pg/mL, *P*\<0.001). When subgroup analyses were performed, significant differences in betatrophin levels between the non-converter and converter groups were noted in both subjects \<70 years of age (909±368 pg/mL vs. 1,225±657 pg/mL, *P*\<0.001) and ≥70 years of age (1,250±456 pg/mL vs. 1,405±520 pg/mL, *P*=0.045), men (1,124±428 pg/mL vs. 1,591±707 pg/mL, *P*\<0.001), and non-obese (1,057±409 pg/mL vs. 1,473±651 pg/mL, *P*\<0.001) groups, but not in women or obese groups ([Fig. 1](#F1){ref-type="fig"}). However, when the non-converter group was further divided into normal glucose tolerance (NGT) and prediabetes groups, a significant stepwise increase in baseline serum betatrophin levels were observed in both men (NGT, 1,103±419 pg/mL; prediabetes, 1,143±441 pg/mL; diabetes converter, 1,591±707 pg/mL; *P* for trend \<0.001) and women (NGT, 939±409 pg/mL; prediabetes, 1,096±471 pg/mL; diabetes converter, 1,155±458 pg/mL; *P* for trend=0.018) ([Fig. 2](#F2){ref-type="fig"}).

To evaluate the role of serum betatrophin in predicting the development of diabetes, we performed log-binomial regression analyses ([Table 3](#T3){ref-type="table"}). In the crude analysis, there was a statistically significant association between higher betatrophin concentrations and an increased risk of incident diabetes. After adjusting for age, sex, and BMI (model 1) and further adjusting for fasting glucose, systolic BP, TC, and family history of diabetes (model 2), this association remained significant. These results suggest that subjects with serum betatrophin concentrations in the highest quartile have more than a threefold increased risk of developing diabetes in the future.

DISCUSSION
==========

In this nested case-control study from a population-based prospective cohort, we found that baseline serum betatrophin levels were significantly higher in the diabetes converter group compared to the non-converter group. There was a stepwise increase in the risk of developing diabetes according to the serum betatrophin levels. After 4 years of follow-up, subjects in the highest baseline quartile of betatrophin levels had more than a threefold higher risk of incident diabetes than the subjects in the lowest quartile. Our findings indicate a possible role of circulating betatrophin as an additional biomarker for identifying individuals at high risk of developing diabetes.

\'Betatrophin\' was first named by the Melton group \[[@B9]\]. Microarray analysis of mouse liver treated with S961, a peptide that binds to insulin receptors and antagonizes insulin signaling, identified an upregulated gene which they called betatrophin. Betatrophin mRNA was expressed in mouse liver and adipose tissue, whereas liver was the primary organ that expressed betatrophin in human. They also showed that betatrophin encodes a liver-secreted protein leading to pancreatic β-cell proliferation, β-cell mass expansion, and improved glucose tolerance in mice. Although this attractive finding caught attention as a possible candidate of regenerative therapy for diabetes, subsequent studies strongly argued the effect of betatrophin in similar settings \[[@B31][@B32][@B33][@B34]\]. ANGPTL8-deficient mice showed normal β-cell expansion in response to insulin resistance and no alterations in glucose homeostasis \[[@B31][@B32]\]. Furthermore, ANGPTL8 overexpression did not increase β-cell replication in mice \[[@B32][@B34]\]. The effect of S961 treatment, which induces betatrophin gene expression and β-cell replication in mice, was not replicated in human β-cells \[[@B33]\]. A recent study with a different approach examined the effect of betatrophin-overexpressed adipose-derived mesenchymal stem cells and demonstrated that co-culture of human islets with these cells increased islet proliferation and insulin secretion \[[@B35]\]. Although the role of betatrophin is still being debated, the original article by the Melton group was recently retracted due to a lack of reproducibility.

Despite dissapointing observations in animal studies, many association studies in humans suggest a possible role of betatrophin in glucose and lipid metabolism. Circulating betatrophin levels were generally higher in metabolically disturbed states, such as type 1 diabetes mellitus \[[@B10][@B21]\], type 2 diabetes mellitus (T2DM) \[[@B11][@B13][@B15][@B16][@B17][@B18][@B21][@B22][@B24][@B25][@B36]\], overweight \[[@B19]\] or obesity \[[@B23]\], metabolic syndrome \[[@B37]\], and nonalcoholic fatty liver disease \[[@B38]\]. However, contradictory results were also reported with either no difference or lower levels of betatrophin in subjects with T2DM, obesity, and dyslipidemia when compared to control groups \[[@B12][@B14][@B19][@B26]\]. Correlation analyses between circulating betatrophin levels and clinical parameters in various studies also yielded inconsistent results. The role of betatrophin in TG metabolism is evidenced by preclinical studies. Overexpression of betatrophin in the liver increased TG levels, whereas knockout mice had lower TG levels, which was linked to lipoprotein lipase activity \[[@B31][@B32][@B39]\]. In humans, several investigations showed a positive correlation between serum betatrophin and TG levels \[[@B16][@B18][@B21]\], while we and others \[[@B10]\] found no such relationship. Whether betatrophin levels are associated with insulin resistance or β-cell function is also a matter of debate. Our results showed no correlation, which is in line with several studies \[[@B12][@B16][@B27]\], while other studies suggested either a positive correlation with the insulin resistance index \[[@B17][@B19]\] or a negative correlation with insulin secretory capacity \[[@B20]\].

The reason for these inconsistencies remains unclear. A meta-analysis suggested a possible difference in the relationship between betatrophin levels and T2DM according to ethnicity \[[@B28]\]. Different ELISA kits, which use antibodies against the N-terminus or C-terminus of betatrophin, detect either the full-length form or both the full-length and the cleaved form, respectively \[[@B40]\]. Although it is unclear which form of betatrophin is functional and how the proteolytic cleavage is controlled, it should be noted that use of different ELISA kits could lead to contrasting results. The inconsistency among studies might also arise from the small number of samples with different clinical characteristics or selection bias. Because the methods used to measure the degree of insulin resistance in previous studies were not the gold standard, further studies using more precise methods and a larger study population are needed to draw definitive conclusions.

To the best of our knowledge, our analysis is the first prospective study to examine the predictive value of betatrophin levels in identifying subjects at high-risk of developing diabetes. In another prospective study, Wang et al. \[[@B27]\] observed that the baseline betatrophin levels were inversely correlated with incident metabolic syndrome in 153 chinese adults after a 3.5-year follow-up. Interestingly, the odds ratio for high blood glucose (≥5.6 mmol/L) component was significantly lower in subjects with three higher quartiles of betatrophin when compared to the lowest quartile group in men, but not in women.

Some limitations should be acknowledged. Because our cohort consisted mainly of middle aged or elderly Koreans, the ability to generalize these findings to other populations of different ages and ethnicities is limited. In particular, several studies revealed a positive correlation between betatrophin levels and age \[[@B15][@B16][@B21][@B27]\]. Furthermore, the type of diabetes could not be determined due to the lack of C-peptide or autoantibody data, but we assume that the majority of the cases would be T2DM based on the age of the study population. Lastly, the HOMA index is limited in its ability to precisely reflect the degree of insulin resistance and β-cell function, although it is practical for large epidemiologic studies.

In conclusion, we propose that the circulating level of betatrophin could be a potential biomarker for predicting new-onset diabetes. Further studies are needed to understand the underlying mechanism of this association and to resolve remaining contradictory issues.
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###### Characteristics of participants according to their diabetes status at follow-up

![](dmj-42-53-i001)

  Characteristic               Non-converter (*n*=167)   DM converter (*n*=167)   *P* value
  ---------------------------- ------------------------- ------------------------ -----------
  Baseline                                                                        
   Age, yr                     68.1±8.1                  68.2±8.3                 0.873
   Male sex, %                 36.5                      36.5                     1.000
   Height, cm                  155.5±8.4                 154.8±8.3                0.465
   Weight, kg                  59.8±8.9                  59.1±9.6                 0.458
   Waist circumference, cm     90.0±8.5                  89.9±9.4                 0.933
   BMI, kg/m^2^                24.8±3.4                  24.6±4.0                 0.754
   Systolic BP, mm Hg          144.3±19.5                146.0±18.6               0.406
   Diastolic BP, mm Hg         85.3±10.0                 84.5±10.3                0.461
   FPG, mmol/L                 5.32±0.54                 5.52±0.58                0.001
   Fasting insulin, pmol/L     25.5 (14.2--46.9)         31.4 (17.3--44.8)        0.252
   HOMA-IR                     0.91 (0.47--1.57)         1.09 (0.61--1.55)        0.126
   HOMA-β                      41.7 (24.2--73.6)         46.3 (25.4--72.0)        0.734
   Total cholesterol, mmol/L   4.78±0.78                 5.00±0.95                0.021
   Triglycerides, mmol/L       1.41 (0.95--2.13)         1.56 (1.02--2.22)        0.464
   HDL-C, mmol/L               1.21±0.30                 1.27±0.37                0.120
   LDL-C, mmol/L               2.82±0.73                 2.94±0.85                0.178
   Serum creatinine, µmol/L    64.4±14.4                 65.2±14.6                0.648
   eGFR, mL/min/1.73 m^2^      93.5±20.9                 91.9±19.2                0.465
   hsCRP, mg/L                 0.12 (0.07--0.23)         0.11 (0.07--0.25)        0.730
   Betatrophin, pg/mL          1,072±446                 1,315±598                \<0.001
   Hypertension, %             46.1                      55.7                     0.080
   Family history of DM, %     10.8                      20.1                     0.019
   Smoking, %                                                                     0.891
    None                       66.5                      64.0                     
    Ex-smoker                  22.7                      24.0                     
    Current                    10.8                      12.0                     
   Alcohol drinking, %         58.1                      41.3                     0.002
   Regular exercise, %         7.8                       7.2                      0.835
  Follow-up                                                                       
   FPG, mmol/L                 5.18±0.52                 5.99±1.12                \<0.001
   Glucose~30~, mmol/L         9.21±1.72                 10.96±2.17               \<0.001
   Glucose~120~, mmol/L        7.68±1.74                 12.68±2.57               \<0.001
   Fasting insulin, pmol/L     28.0 (13.3--47.6)         44.3 (16.1--64.8)        0.001
   HOMA-IR                     0.96 (0.39--1.59)         1.66 (0.55--2.49)        \<0.001
   HOMA-β                      59.4 (21.5--95.0)         59.9 (23.0--83.6)        0.526

Values are presented as mean±standard deviation or median (interquartile range).

DM, diabetes mellitus; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment estimate of β-cell function; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein.

###### Serum betatrophin concentrations according to characteristics of participants
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  Characteristic           No.   Mean±SD, pg/mL   *P* value
  ------------------------ ----- ---------------- -----------
  Age, yr^a^                                      \<0.001
   \<70                    171   1,064±552        
   ≥70                     163   1,329±494        
  Sex                                             \<0.001
   Men                     122   1,358±627        
   Women                   212   1,099±459        
  BMI, kg/m^2^                                    0.009
   \<25                    175   1,266±581        
   ≥25                     159   1,113±480        
  WC, cm                                          0.032
   \<80 (W), 90 (M)        49    1,347±583        
   ≥80 (W), 90 (M)         285   1,167±529        
  Metabolic syndrome                              0.130
   No                      115   1,255±532        
   Yes                     219   1,161±543        
  Triglycerides, mmol/L                           0.274
   \<1.69                  194   1,220±576        
   ≥1.69                   140   1,156±487        
  eGFR, mL/min/1.73 m^2^                          0.124
   \<60                    12    1,429±490        
   ≥60                     322   1,185±541        
  Hypertension                                    0.026
   No                      164   1,126±527        
   Yes                     170   1,258±547        
  Alcohol drinking                                0.625
   No                      168   1,208±481        
   Yes                     166   1,179±596        
  HOMA-IRa                                        0.142
   \<1.0                   182   1,233±541        
   ≥1.0                    152   1,146±537        

BMI, body mass index; WC, waist circumference; W, women; M, men; eGFR, estimated glomerular filtration rate; HOMA-IR, homeostasis model assessment of insulin resistance.

^a^Subgroups were divided according to the approximate mean or median value of the study population.

###### Risk of developing diabetes according to quartiles of serum betatrophin concentrations
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              No. of converter (%)   Crude                  Model 1^a^             Model 2^b^
  ----------- ---------------------- ---------------------- ---------------------- ----------------------
  Q1          33 (39.8)              1 (reference)          1 (reference)          1 (reference)
  Q2          37 (44.1)              1.193 (0.645--2.207)   1.301 (0.690--2.452)   1.362 (0.698--2.657)
  Q3          46 (55.4)              1.884 (1.016--3.491)   2.167 (1.122--4.183)   2.063 (1.036--4.107)
  Q4          51 (60.7)              2.342 (1.259--4.355)   2.854 (1.427--5.708)   3.275 (1.574--6.814)
  *P* value   0.023                  0.025                  0.012                  0.010

Values are presented as relative risks (95% confidence interval).

^a^Model 1: Adjusted for age, sex, and body mass index, ^b^Model 2: Adjusted for model 1+fasting glucose, systolic blood pressure, total cholesterol, and family history of diabetes.
